Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31344502 | 1.00 | RIPK1 (0.49) | RIPK1KMT2AMEN1HPGDLMNA | |
| SCHEMBL17198941 | 0.86 | RIPK1 (0.44) | RIPK1KMT2AMEN1HPGDLMNA | |
| Hydrochloric Acid SCHEMBL30496712 | 0.84 | RIPK1 (0.43) | RIPK1KMT2AMEN1HPGDLMNA | |
| Hydrochloric Acid SCHEMBL8004974 | 0.82 | PPIA (0.51) | RIPK1KMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL3916714 | 0.81 | TAAR1 (0.55) | KMT2AMEN1HPGDALDH1A1TAAR1 | |
| SCHEMBL22319029 | 0.81 | ALDH1A1 (0.47) | RIPK1KMT2AMEN1HPGDLMNA | |
| SCHEMBL30496749 | 0.81 | TAAR1 (0.55) | KMT2AMEN1HPGDALDH1A1TAAR1 | |
| SCHEMBL5532672 | 0.81 | KMT2A (0.55) | RIPK1KMT2AMEN1HPGDLMNA | |
| SCHEMBL5527359 | 0.81 | ALDH1A1 (0.59) | RIPK1KMT2AMEN1HPGDLMNA | |
| Hydrochloric Acid SCHEMBL28482472 | 0.80 | TAAR1 (0.53) | KMT2AMEN1HPGDALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3218333-B1 | FLUORIDE TRAPPING ARRANGEMENT | GE HEALTHCARE LTD (GB) | 2023-06-07 | — | — | EP | claimed |
| EP-2948188-A1 | NEURONAL IMAGING AND TREATMENT | Tylerton International Holdings Inc. (VG) | 2015-12-02 | — | — | EP | disclosed |
| EP-1799684-B1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-12-03 | — | — | EP | disclosed |
| WO-2014115152-A1 | NEURONAL IMAGING AND TREATMENT | TYLERTON INTERNATIONAL HOLDINGS INC. (VG) | 2014-07-31 | — | — | WO | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7429565-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | RIPK1 197/4885KMT2A 2007/4885MEN1 1532/4885 |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | PRKCI, PIK3CA, AKT1 | RIPK1 197/4885KMT2A 2007/4885MEN1 1532/4885 |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | RIPK1 197/4885KMT2A 2007/4885MEN1 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.